Abarelix vs Cetrorelix
Research Verdict
Abarelix is the stronger research reference for the stated comparison criteria. Abarelix: FDA approved 2003 for advanced prostate cancer, withdrawn from US market due to 3.7% immediate-onset systemic allergic reaction rate.
Quick Answers
Which is better, Abarelix or Cetrorelix?
Abarelix is the stronger research reference for the stated comparison criteria. Abarelix: FDA approved 2003 for advanced prostate cancer, withdrawn from US market due to 3.7% immediate-onset systemic allergic reaction rate.
What is the key difference between Abarelix and Cetrorelix?
Abarelix carried a clinically significant anaphylaxis risk (3.7%) requiring 30-minute post-injection monitoring; cetrorelix has standard injectable side effects without this systemic allergic concern - a critical safety distinction.
Evidence Comparison
Abarelix: FDA approved 2003 for advanced prostate cancer, withdrawn from US market due to 3.7% immediate-onset systemic allergic reaction rate. Cetrorelix: approved in multiple countries for controlled ovarian stimulation in IVF, well-established safety profile. Cetrorelix has a cleaner safety record and remains in active clinical use.
Evidence Context Favoring Abarelix
Historical research into prostate cancer GnRH antagonism or study of peptide-induced anaphylaxis mechanisms.
Evidence Context Favoring Cetrorelix
Any clinical application requiring a GnRH antagonist with an acceptable safety profile - cetrorelix is the standard of care in fertility medicine.
Side-by-Side Snapshot
| Evidence grade | Abarelix: Level A Cetrorelix: Level A |
|---|---|
| Research status | Abarelix: Historical FDA Approval Cetrorelix: FDA Approved |
| Primary category | Abarelix: Sexual Health Cetrorelix: Sexual Health |
| Cited studies | Abarelix: 2 Cetrorelix: 2 |